Abstract
Background Patients with cirrhosis undergoing therapeutic paracentesis are at risk of developing kidney injury, but this has not been well evaluated in a non-large volume paracentesis setting.
Objective The aims of this study were to determine the risk and consequence of acute kidney injury (AKI) and its progression in patients with decompensated cirrhosis after moderate volume paracentesis by use of a urine test measuring tissue inhibitor of metalloproteinases-2 (TIMP2) and (IGFBP7).
Methods A randomized, prospective cohort study was performed. All outpatients with decompensated cirrhosis with ascites and diuretic complications were enrolled and randomized into 3 liters and 5 liters of paracentesis groups. Serial urine samples were analyzed for [TIMP2]*[IGFBP7] concentration before and after paracentesis.
Results A total of 90 patients with decompensated cirrhosis were consecutively enrolled during the study period. After screening, 29 patients were enrolled in the 3-liter paracentesis group, and 25 patients were enrolled in the 5-liter paracentesis group. The mean of the MELD score was 8 ± 1.2. Urine TIMP2.IGFBP7>2, rising urine TIMP2, and rising urine TIMP2/urine Cr were shown in patients within the 5-liter group for 48% (p = 0.015), 32% (p = 0.049) and 76% (p =0.010), respectively. There was no statistical difference between the two groups in the rapid decline of GFR, admission, or death.
Conclusion Urine TIMP2.IGFBP7>2 predicted renal tubular injury in patients in the ascites release 5 L group therefore, ascites release 5 L may not be safe. Kidney injury could occur even less than 5 liters of ascites release in decompensated cirrhosis as demonstrated.
The national clinical registration number was TCTR20191116003.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Trial registration number: TCTR20191116003
Funding Statement
Yes
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Trial Registration: The informed consent regulation provided by the Institutional Review Board of the Royal Thai Army Medical Department Committee (IRB number R164h/61) and registered at www.clinicaltrials.in.th. Trial registration number: TCTR20191116003
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Data Availability
The data that support the findings of this study are available on request from the corresponding author, [SC]. The data are not publicly available due to their containing information that could compromise the privacy of research participants.
